Close this search box.
Subscriber Log In

Q1 2024 Round Up: Situation Normal?

As 2023 drew to a close, the biopharma industry began to shake off its previous struggles. Has this positive momentum carried into the early months of this year?

The early signs are promising. M&A activity increased notably in Q1; and although the total value was moderate, the volume of deals was significant. This impetus also helped to improve the IPO market, which is showing signs of recovery. While only a few of the newly public companies are performing above expectations, others are gradually finding their footing.

Venture capital fundraising has also been on the rise since late last year, with investors focusing on fewer, but larger funding rounds. Additionally, the surge in interest in obesity drugs has energised the stock market, attracting a wider range of investors.

Our Q1 Round Up analyses the trends and outcomes in M&A, venture funding, stock market performance, and the pace of IPOs.

Download your copy now for key insights from Q1:

  • Who’s driving $36+bn in M&A deals?
  • Why is the VC rebound uneven?
  • Are the IPO highs and lows fading?
  • Who are the top 10 share price winners and losers?


Related Blogs

Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.